Search research articles
Contact Us
Filters
Showing results (41-50 of 58) with videos related to
Page
of 6
Sort By:
Lancet (London, England)
|
June 27, 2001
25-hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue
V Tangpricha, J N Flanagan, L W Whitlatch, et al.
Anticancer Research
|
August 5, 2006
Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D
John N Flanagan, Michael V Young, Kelly S Persons, et al.
Anticancer Research
|
August 5, 2006
Analysis of 25-hydroxyvitamin D3-1alpha-hydroxylase in normal and malignant breast tissue
Michael Friedrich, Dagmar Diesing, Tim Cordes, et al.
The Journal of Steroid Biochemistry and Molecular Biology
|
September 14, 2011
Substitution at carbon 2 of 19-nor-1α,25-dihydroxyvitamin D3 with 3-hydroxypropyl group generates an analogue with enhanced chemotherapeutic potency in PC-3 prostate cancer cells
Diego Iglesias-Gato, Shasha Zheng, John N Flanagan, et al.
Carcinogenesis
|
January 20, 2004
The prostate 25-hydroxyvitamin D-1 alpha-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D
Michael V Young, Gary G Schwartz, Lilin Wang, et al.
The Journal of Steroid Biochemistry and Molecular Biology
|
July 26, 2002
25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer
Lyman W Whitlatch, Michael V Young, Gary G Schwartz, et al.
The Journal of Clinical Endocrinology and Metabolism
|
May 28, 2009
Role of follistatin in promoting adipogenesis in women
John N Flanagan, Kristina Linder, Niklas Mejhert, et al.
Anticancer Research
|
July 25, 2008
Prostate 25-hydroxyvitamin D-1alpha-hydroxylase is up-regulated by suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor
Lilin Wang, Kelly S Persons, Dan Jamieson, et al.
American Journal of Human Genetics
|
March 25, 2000
Evidence for variable selective pressures at MC1R
R M Harding, E Healy, A J Ray, et al.
The Journal of Clinical Endocrinology and Metabolism
|
December 4, 2019
Muscle Strength, Size, and Composition Following 12 Months of Gender-affirming Treatment in Transgender Individuals
Anna Wiik, Tommy R Lundberg, Eric Rullman, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 58) with videos related to
Sort By:
Page
of 6
Lancet (London, England)
|
June 27, 2001
25-hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue
V Tangpricha, J N Flanagan, L W Whitlatch, et al.
Anticancer Research
|
August 5, 2006
Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D
John N Flanagan, Michael V Young, Kelly S Persons, et al.
Anticancer Research
|
August 5, 2006
Analysis of 25-hydroxyvitamin D3-1alpha-hydroxylase in normal and malignant breast tissue
Michael Friedrich, Dagmar Diesing, Tim Cordes, et al.
The Journal of Steroid Biochemistry and Molecular Biology
|
September 14, 2011
Substitution at carbon 2 of 19-nor-1α,25-dihydroxyvitamin D3 with 3-hydroxypropyl group generates an analogue with enhanced chemotherapeutic potency in PC-3 prostate cancer cells
Diego Iglesias-Gato, Shasha Zheng, John N Flanagan, et al.
Carcinogenesis
|
January 20, 2004
The prostate 25-hydroxyvitamin D-1 alpha-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D
Michael V Young, Gary G Schwartz, Lilin Wang, et al.
The Journal of Steroid Biochemistry and Molecular Biology
|
July 26, 2002
25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer
Lyman W Whitlatch, Michael V Young, Gary G Schwartz, et al.
The Journal of Clinical Endocrinology and Metabolism
|
May 28, 2009
Role of follistatin in promoting adipogenesis in women
John N Flanagan, Kristina Linder, Niklas Mejhert, et al.
Anticancer Research
|
July 25, 2008
Prostate 25-hydroxyvitamin D-1alpha-hydroxylase is up-regulated by suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor
Lilin Wang, Kelly S Persons, Dan Jamieson, et al.
American Journal of Human Genetics
|
March 25, 2000
Evidence for variable selective pressures at MC1R
R M Harding, E Healy, A J Ray, et al.
The Journal of Clinical Endocrinology and Metabolism
|
December 4, 2019
Muscle Strength, Size, and Composition Following 12 Months of Gender-affirming Treatment in Transgender Individuals
Anna Wiik, Tommy R Lundberg, Eric Rullman, et al.
Page
of 6